The only known, effective intervention for non-alcoholic fatty liver disease (NAFLD) is weight loss, and there is no approved pharmacotherapy. Recently, new hypoglycemic agents, such as sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1RAs), and their effects on NAFLD have received substantial interest. Herein, we review the currently available human studies regarding the effects of SGLT2 inhibitors and GLP-1RAs on NAFLD/non-alcoholic steatohepatitis in patients with type 2 diabetes mellitus, and we describe the possible mechanisms explaining the positive effects of these agents on NAFLD.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6484938 | PMC |
| http://dx.doi.org/10.7570/jomes.2019.28.1.18 | DOI Listing |
Publication Analysis
Top Keywords
hypoglycemic agents
8
non-alcoholic fatty
8
fatty liver
8
liver disease
8
sodium-glucose cotransporter
8
inhibitors glucagon-like
8
glucagon-like peptide-1
8
peptide-1 receptor
8
receptor agonists
8
sglt2 inhibitors
8
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!